PDF file: 441-2153_Ivermectin_part_1_phil.pdf
OPQ ID: 441-2153
Session: 441
Question number: Q-2153
Sessional paper: Q-2153
Title: Ivermectin, part 1, phil
Short description: 
Topic: public health
Identified concern: 
Keywords: 
Agencies: HC, PHAC
Date asked: 2023-12-12
Date tabled: 
Submitted by: Mr. Falk (Provencher)
Reply by: Minister of Health
Responded by: the Honourable Mark Holland
Pages: 2
Status: not processed
Alert: yellow
Questions asked: 4
Questions answered: 3
Percent responded: 75%
Referenced sources: Canada.ca
Referenced links: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS00498.However, https://recalls-rappels.canada.ca/en/alert-recall/ivermectin-not-authorizedprevent-or-treat-covid-19-may-cause-serious-health-problems
Official link: https://www.google.com/search?q=Q-2153+ourcommons.ca
PDF URL: https://ivim.ca/foi/opq/r/441-2153_Ivermectin_part_1_phil.pdf
TXT URL: https://ivim.ca/foi/opq/r/441-2153.txt
Original filename: Q-2153_HC, Ivermectin, part 1, phil.pdf
Local source path: C:\Users\Dmitry\Documents\CODES\OPQ-App\data-raw\OPQ\ALL OPQ TO DATE\2022\Q-2153_HC, Ivermectin, part 1, phil.pdf
Machine extracted at: 2026-06-30 12:58:25

References / links:
- https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS00498.However
- https://recalls-rappels.canada.ca/en/alert-recall/ivermectin-not-authorizedprevent-or-treat-covid-19-may-cause-serious-health-problems(b
- Canada.ca

Machine notes:
(none)

Question text preview:
With regard to Public Health Agency of Canada (PHAC), the Ad-hoc COVID-19 Clinical Pharmacology Task Group and Health Canada (HC) research or communication about lvermectin: (a) did they find any harm to Canadians from taking oral lvermectin to prevent or treat COVID19;
(b) did HC, PHAC, or a committee review the lvermectin meta-analysis conducted by Andrew Bryant, lvermectin for Prevention and
Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines, American
Journal of Therapeutics, 28, e434-e460, July 2021, (i) did their analysis show any benefit from using lvermectin to prevent or treat COVID19;
(c) did HC or PHAC perform a risk-harm analysis for the use of lvermectin to prevent or treat COVID-19, (i) if the answer to (c) is negative, why not, (ii) if the answer to (c) is affirmative, was this information provided to Dr.
Theresa Tam, Dr.
Supryia Sharma, or the
Minister of Health, (iii) what dates was the information from (ii) communicated, (iii) if the answer to (ii) is negative, why not?